Advanced

Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.

Andersson, Roland LU ; Aho, Ursula LU ; Nilsson, Bo; Peters, Godefridus; Pastor-Anglada, Marcal; Rasch, Wenche and Sandvold, Marit (2009) In Scandinavian Journal of Gastroenterology 44. p.782-786
Abstract
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1... (More)
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Gastroenterology
volume
44
pages
782 - 786
publisher
Taylor & Francis
external identifiers
  • WOS:000268579400003
  • PMID:19214867
  • Scopus:70350635407
ISSN
1502-7708
DOI
10.1080/00365520902745039
language
English
LU publication?
yes
id
0340dab7-0cd1-48b5-b48d-4b1196e0f759 (old id 1302576)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19214867?dopt=Abstract
date added to LUP
2009-03-02 14:57:08
date last changed
2016-11-20 04:24:28
@misc{0340dab7-0cd1-48b5-b48d-4b1196e0f759,
  abstract     = {Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.},
  author       = {Andersson, Roland and Aho, Ursula and Nilsson, Bo and Peters, Godefridus and Pastor-Anglada, Marcal and Rasch, Wenche and Sandvold, Marit},
  issn         = {1502-7708},
  language     = {eng},
  pages        = {782--786},
  publisher    = {ARRAY(0x92d0f38)},
  series       = {Scandinavian Journal of Gastroenterology},
  title        = {Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.},
  url          = {http://dx.doi.org/10.1080/00365520902745039},
  volume       = {44},
  year         = {2009},
}